Baird lowered the firm’s price target on Iqvia to $235 from $241 and keeps a Neutral rating on the shares. The firm sees a moderate recovery in TAS and RDS CDO growth but more importantly TAS has to pick up steam soon, as big Q4 ramp required remains a difficult to insurmountable sentiment hurdle for most investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $255 from $275 at Barclays
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Dollar Tree downgraded, Lululemon upgraded: Wall Street’s top analyst calls
- Iqvia initiated with a Buy at Goldman Sachs
- Here’s what Wall Street experts are saying about Salesforce ahead of earnings